Home » Topics » Lung Cancer
Lung Cancer
FEATURED
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
LATEST FEATURES
A systematic review revealed characteristics that may help clinicians predict which patients will benefit from immunotherapy.
The biosimilars proved as effective as the original biologics in all cancers studied.
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
All features >>
LATEST NEWS
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.
The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.
After implementation of the USPSTF 2021 criteria for lung cancer screening, there was an increase in the proportion of African-American individuals who underwent screening.
Load More
Open
Next post in Lung Cancer
Close
Close more info about Rate of CRT-Related Pneumonitis in NSCLC May Be Higher in Real World Than in Clinical Trials
Loading...
Close more info about Rate of CRT-Related Pneumonitis in NSCLC May Be Higher in Real World Than in Clinical Trials
Loading...